NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Stride investors who were adversely affected by alleged securities fraud between October 22, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Firefly Aerospace Inc. ("Firefly Aerospace Inc." or the "Company") (NASDAQ: FLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Firefly Aerospace Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired: (a) Firefly ...

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was claimed to be less effective than represented [2]. - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Freeport-McMoRan Inc. ("Freeport-McMoRan Inc." or the "Company") (NYSE: FCX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Freeport-McMoRan Inc. investors who were adversely affected by alleged securities fraud between February 15, 2022 and September 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected investors between June 20, 2025, and November 5, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that defendants made false statements regarding CarMax's growth prospects, suggesting that earlier growth was due to temporary factors related to customer behavior influenced by tariff speculation [2]. - It is alleged that the statements made by defendants about CarMax's business operations and future prospects were materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 2, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Gauzy Ltd. for alleged violations of securities laws, specifically related to misleading statements made by the company regarding its financial health and debt obligations [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased by investors between March 11, 2025, and November 13, 2025, during which the company allegedly made false and misleading statements [2]. - Investors are encouraged to contact the Schall Law Firm before February 6, 2026, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Gauzy's subsidiaries in France were unable to repay debts as they became due, leading to potential defaults on senior secured debt facilities [4]. - The company's public statements during the class period are claimed to be false and materially misleading, resulting in investor damages once the truth was revealed [4].

Core Insights - CarMax, Inc. is a leading retailer of used vehicles in the U.S., operating through two segments: CarMax Sales Operations and CarMax Auto Finance, known for no-haggle pricing and comprehensive vehicle inspections [1] - The company is currently facing a class action securities lawsuit alleging securities fraud, which could impact investor sentiment and stock performance [3] - Evercore ISI has set a price target of $37 for CarMax, indicating potential downside from its current trading price of $39.26, which reflects a 5.76% premium over the target [2][5] - The stock has shown significant volatility, with a 52-week high of $91.25 and a low of $30.26, indicating active trading and investor interest [4][5] - CarMax's market capitalization is approximately $5.98 billion, with a trading volume of 3,230,319 shares on the NYSE [4]

San Diego, California--(Newsfile Corp. - December 9, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the "Class Period"), have until Monday, January 12, 2026 to seek appointment as lead plaintiff of the Freeport-McMoRan class action lawsuit. Captioned Reed v. Freeport-McMoRan Inc., No. 25-cv-04243 (D. Ariz.), the Freeport-McMoRan class ...

PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...